4/A//SEC Filing
Sumitovant Biopharma Ltd. 4/A
Accession 0000899243-20-012574
CIK 0001679082other
Filed
May 10, 8:00 PM ET
Accepted
May 11, 4:07 PM ET
Size
10.1 KB
Accession
0000899243-20-012574
Insider Transaction Report
Form 4/AAmended
Sumitovant Biopharma Ltd.
10% Owner
Transactions
- Purchase
Common Stock
2020-05-06$12.24/sh+50,000$612,075→ 48,247,693 total(indirect: See Footnote)
Sumitomo Chemical Co., Ltd.
10% Owner
Transactions
- Purchase
Common Stock
2020-05-06$12.24/sh+50,000$612,075→ 48,247,693 total(indirect: See Footnote)
Dainippon Sumitomo Pharma Co Ltd
10% Owner
Transactions
- Purchase
Common Stock
2020-05-06$12.24/sh+50,000$612,075→ 48,247,693 total(indirect: See Footnote)
Footnotes (4)
- [F1]On May 7, 2020, the Reporting Persons filed a Form 4 disclosing the acquisition of 50,000 shares of Common Stock at an average stock price of $11.6893 (the "First Acquisition") and 50,000 shares of Common Stock at an average stock price of $12.2415 (the "Second Acquisition"). The transaction date reported in Box 2 for both the First Acquisition and the Second Acquisition was May 5, 2020. The transaction date for the Second Acquisition was incorrectly reported and should have been reported as May 6, 2020.
- [F2]This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020.
- [F3]The price reported in column 4 is the average stock price.
- [F4]Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
Documents
Issuer
Myovant Sciences Ltd.
CIK 0001679082
Entity typeother
IncorporatedBermuda
Related Parties
1- filerCIK 0001798244
Filing Metadata
- Form type
- 4/A
- Filed
- May 10, 8:00 PM ET
- Accepted
- May 11, 4:07 PM ET
- Size
- 10.1 KB